Rajiv Aggarwal
Neurology · Burnsville, MNNPI 1942247986
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Pfizer at 29.8% of the total. 2025 is the largest year on record at $1,755, 9.2 times the $191 reported in 2019.
Across 95 payments — averaging $61.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Biohaven Pharmaceutical Holding Company Ltd.$1K
- AbbVie$564
- Novartis$127
- UCB, Inc.$92
- plus $1K from 33 others
Across 430 payments — averaging $4315.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Eli Lilly$531K
- Ipsen Innovation$192K
- Teva Pharmaceuticals USA, Inc.$47K
- Biogen$10K
What the payments were for
- Consulting fees$1,52526%
- Speaking & faculty fees$2,25038%
- Travel & lodging$2374%
- Food & beverage$1,84031%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $1,747 |
| Biohaven Pharmaceuticals, Inc. | 2 | $1,133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $1,125 |
| AbbVie(2 entities) | 11 | $564 |
| Novartis | 7 | $127 |
| UCB, Inc. | 4 | $92 |
| Biogen | 6 | $89 |
| Eisai Inc. | 4 | $75 |
| Boston Scientific | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Kyowa Kirin, Inc. | 2 | $55 |
| Neurelis, Inc. | 3 | $55 |
| AstraZeneca | 2 | $51 |
| CSL Behring | 3 | $51 |
| Adamas Pharmaceuticals, Inc. | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 3 | $45 |
| EMD Serono, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Argenx US, Inc. | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Johnson & Johnson | 2 | $27 |
| Harmony Biosciences LLC | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Kedrion Biopharma Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Banner Life Sciences, LLC | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $17 |
| TG Therapeutics, Inc. | 1 | $17 |
| GE HealthCare | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Akcea Therapeutics, Inc. | 1 | $15 |
| Hospira, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$3,910
- BOTOX$426
How this compares
$5,860 in reported general payments places this provider in the 80th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 16 | $80,097 |
| Emgality PenGalcanezumab-Gnlm | 35 | $33,130 |
| Nurtec OdtRimegepant Sulfate | 15 | $29,149 |
| Gabapentin | 311 | $8,433 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 118 | $5,557 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 13 | $4,678 |
| RivastigmineRivastigmine Tartrate | 38 | $2,558 |
| Lacosamide | 29 | $2,487 |
| Donepezil Hcl | 173 | $2,361 |
| Levetiracetam | 53 | $2,304 |
| Memantine Hcl | 110 | $2,285 |
| Carbamazepine | 27 | $1,878 |
| Duloxetine Hcl | 80 | $1,538 |
| Primidone | 46 | $1,469 |
| Topiramate | 56 | $1,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $20 | $80,09716 claims |
| PfizerNurtec Odt | $1,747 | $29,14915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 neurology providers in Minnesota.
Other neurology in Burnsville
- Jeffery AllenMinneapolis$1.1M
- Jonathan CalkwoodGolden Valley$493K
- Alejandro RabinsteinRochester$305K
- Patricia PenovichSaint Paul$304K
- Sean PittockRochester$231K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Akram DastagirGolden Valley$174K
- Jessica HeiringGolden Valley$149K
- Shelly Larson-PetersBlaine$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.